- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06630884
Ontstekingsuitdaging en angst (LIFE)
Ontstekingsuitdaging en uitroeiing van angst: een model om het begrip van posttraumatische stressstoornis te vergroten
The goal of this study is to learn if short-term changes in the immune system alter how we process information and experience fear. The main questions it aims to answer are:
Do people who receive typhoid vaccine respond differently than those who receive a placebo saline vaccine? Do people who receive typhoid vaccine experience changes in how they think and feel?
Participants will:
Attend four appointments at the San Francisco VA Health Care System;
Receive typhoid vaccine or placebo at one of the visits;
Have their physiological responding measured while listening to sounds;
Complete questionnaires and psychological tests.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Posttraumatic stress disorder (PTSD) is a chronic disorder affecting more than 8% of the general population and two-three times as many women as men. Deficits in fear responding play a critical role in PTSD. Interventions that target fear responding are first-line treatments for PTSD, but they are only partially effective. To develop new and enhanced interventions, we need a better understanding of the factors that influence fear responding in PTSD in both females and males. One such factor is inflammation, which is elevated in response to acute psychological stress and in PTSD. Preclinical models indicate that elevated inflammation in general, and elevated levels of the pro-inflammatory cytokine interleukin-6 (IL-6) in particular, can impair fear responses. People with PTSD and women may be more sensitive to the effects of inflammatory activity on fear responses. The long-term goal is to uncover the mechanistic role that inflammation plays in PTSD in order to identify effective primary and adjunctive anti-inflammatory interventions. The objective in this proposal is to determine the effects of acute inflammatory challenge on fear responding in trauma-exposed women and men with and without PTSD. The central hypothesis is that acute inflammatory challenge will alter fear responding, with particularly strong effects in people with chronic PTSD and women. The aims are to: 1) determine the effects of acute inflammatory challenge on fear responding in individuals with and without PTSD; 2) examine if increases in inflammatory activity mediate associations between acute inflammatory challenge and fear responses; and 3) elucidate sex differences in the effects of acute inflammatory challenge on fear responses. In the proposed study, we will use polysaccharide typhoid vaccine, which preliminary data support as a robust acute inflammatory challenge, and a fear learning paradigm that we have used in >200 people with PTSD. Participants will first undergo physiological testing of fear responses. Then, three days later, participants will receive either vaccine or placebo and undergo more tests, including physiological tests. One week later, we will test physiological responses again. Inflammatory markers will be measured at baseline, twice on the the vaccine/placebo day, and once at the one-week follow-up visit. This proposal is significant and innovative because it would be the first study to examine the effects of acute inflammatory activity on fear responses in trauma-exposed individuals with and without PTSD, and it has potential to elucidate biological mechanisms of impaired fear responses, uncover sex differences, and point us in the direction of novel interventions to treat PTSD.
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Aoife O'Donovan, PhD
- Telefoonnummer: 415-221-4810
- E-mail: aoife.odonovan@ucsf.edu
Studie Contact Back-up
- Naam: Michael Srouji, BA
- Telefoonnummer: 415-221-4810
Studie Locaties
-
-
California
-
San Francisco, California, Verenigde Staten, 94121
- Werving
- San Francisco VA Health Care System
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
All Subjects:
- Aged 18-65 years old
- Trauma Exposed
- Current PTSD/No history of PTSD
Exclusion Criteria:
- Contraindications to typhoid vaccine
- Conditions associated with inflammation
- Pregnancy or plans to become pregnant in next three months
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Polysaccharide typhoid vaccine
Participants in this condition will receive an injection of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA), which contains 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. |
Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever. |
|
Placebo-vergelijker: Saline Placebo Arm
Participants in this condition will receive and injection of 0.5ml of saline. |
The placebo injection will consist of 0.5mL of saline. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Skin conductance response (SCR)
Tijdsspanne: SCR will be assessed at baseline, 4.5 hours, and one week after vaccine/placebo.
|
Skin conductance level (SCL)will be sampled at 1000 Hz beginning 2 s prior to the conditioned stimulus (CS) onset and continuing until 6 s following CS offset. The skin conductance response (SCR) score for each CS interval will be obtained by subtracting the mean SCL for the 2 s preceding CS onset from the peak during the 8 s CS interval. |
SCR will be assessed at baseline, 4.5 hours, and one week after vaccine/placebo.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Heart rate
Tijdsspanne: HR will be assessed at baseline, 4.5 hours, and one week after vaccine/placebo.
|
HR will be calculated by subtracting average HR of every 0.5 s interval during 6 s before CS (baseline) from peak HR during 0.5 s interval of 8 s after CS onset (response). |
HR will be assessed at baseline, 4.5 hours, and one week after vaccine/placebo.
|
|
Eyeblink electromyography (EMG)
Tijdsspanne: Eyeblink EMG will be assessed at baseline, 4.5 hours, and one week after vaccine/placebo.
|
EMG will be calculated by subtracting the mean signal amplitude during 2 s preceding CS onset (baseline) from the peak during the 8 s CS interval (response). |
Eyeblink EMG will be assessed at baseline, 4.5 hours, and one week after vaccine/placebo.
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Aoife O'Donovan, PhD, University of California, San Francisco
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- R01MH135076 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Demographic, clinical, biological, and psychophysiological data will be acquired from 120 individuals with PTSD and 120 individuals without PTSD. Demographic data will be self-reported. Clinical data will include information from validated semi-structured clinical interviews and validated self-report measures assessing symptoms of PTSD and other psychiatric disorders. Biological data will include levels of eleven inflammatory markers derived from five blood draws for each participant. Psychophysiological data will include skin conductance level, heart rate (HR), and HR variability (HRV) assessed 34 times for each participant.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .